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Objectives We investigated whether plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP), a marker of cardiac
dysfunction and prognosis measured in CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure),
could be used to identify the severity of heart failure at which statins become ineffective.
Background Statins reduce cardiovascular morbidity and mortality in many patients with ischemic heart disease but not, overall,
those with heart failure. There must be a transition point at which treatment with a statin becomes futile.
Methods In CORONA, patients with heart failure, reduced left ventricular ejection fraction, and ischemic heart disease
were randomly assigned to 10 mg/day rosuvastatin or placebo. The primary composite outcome was cardiovas-
cular death, nonfatal myocardial infarction, or stroke.
Results Of 5,011 patients enrolled, NT-proBNP was measured in 3,664 (73%). The midtertile included values between
103 pmol/l (868 pg/ml) and 277 pmol/l (2,348 pg/ml). Log NT-proBNP was the strongest predictor (per log
unit) of every outcome assessed but was strongest for death from worsening heart failure (hazard ratio [HR]:
1.99; 95% confidence interval [CI]: 1.71 to 2.30), was weaker for sudden death (HR: 1.69; 95% CI: 1.52 to
1.88), and was weakest for atherothrombotic events (HR: 1.24; 95% CI: 1.10 to 1.40). Patients in the lowest
tertile of NT-proBNP had the best prognosis and, if assigned to rosuvastatin rather than placebo, had a greater
reduction in the primary end point (HR: 0.65; 95% CI: 0.47 to 0.88) than patients in the other tertiles (heteroge-
neity test, p  0.0192). This reflected fewer atherothrombotic events and sudden deaths with rosuvastatin.
Conclusions Patients with heart failure due to ischemic heart disease who have NT-proBNP values 103 pmol/l (868
pg/ml) may benefit from rosuvastatin. (J Am Coll Cardiol 2009;54:1850–9) © 2009 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.041W
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November 10, 2009:1850–9 CORONA: NT-proBNP and Rosuvastatin-type natriuretic peptide and amino-terminal pro-brain na-
riuretic peptide (NT-proBNP) predict mortality in patients
ith heart failure, whether (1–5) or not (6) left ventricular
jection fraction (LVEF) is reduced. Indeed, B-type natriuretic
eptide and NT-proBNP have usually proved superior to any
ther variable in predicting outcome (7,8), and their prognostic
alue may extend far beyond heart failure (8–10).
See page 1860
There is abundant evidence that statins reduce vascular
vents and improve prognosis in a broad range of patients
ith or at increased risk of atherosclerosis (10). However,
he prognosis of some patient groups at very high risk of
vents may not be amenable to modification with statins
11–13). This may be because statins are ineffective in such
atients or because disease progression is not driven pre-
ominantly by progression of atheroma. Most clinical trials
f statins have excluded patients with overt heart failure, but
everal suggested that they could reduce the risk of the
evelopment of heart failure in a patient (14,15). The Heart
rotection Study did not record which patients had heart
ailure at baseline but did measure NT-proBNP using a
oncommercial assay (10,16). The risk of cardiovascular
vents increased as NT-proBNP increased, and, therefore,
lthough the relative benefits of simvastatin declined with
ncreasing plasma concentrations, the absolute benefits were
imilar regardless of the NT-proBNP level (10). However,
nlike in CORONA, few patients in the Heart Protection
tudy had high plasma concentrations of NT-proBNP. In
ORONA, rosuvastatin reduced the rate of atherothrom-
otic events and of cardiovascular hospitalizations, but no
verall effect of rosuvastatin on mortality was demonstrated.
e investigated the possibility of a transition point for
T-proBNP below which patients with heart failure had a
ore favorable outcome and greater benefit from rosuvas-
atin. We also investigated the ability of NT-proBNP to
redict prognosis and mode of death in a large group of
atients with chronic heart failure.
ethods
etailed accounts of the design, enrollment, and patient
haracteristics of CORONA have been reported. In brief,
atients 60 years of age or older with, in the investigators’
pinion, stable, symptomatic heart failure, ischemic heart
isease, and a reduced LVEF were eligible, provided they
ere not taking lipid-lowering drugs. Patients with a history
f intolerance to statins; those experiencing a recent vascular
vent; those with severe uncorrected valve disease, a serum
reatinine of 2.5 mg/dl (221 mol/l), or any condition
ther than heart failure that would substantially reduce life
xpectancy or limit compliance with the protocol; and those
aking 80% of dispensed placebo tablets during the run-in
eriod were excluded. For most purposes, only patients who lad a baseline measurement of
T-proBNP were included in
his analysis.
The trial was approved by the
thics committee at each of the
articipating hospitals, and pa-
ients gave written informed
onsent. Eligible patients were
reated with single-blind placebo
o demonstrate compliance for as
ong as 4 weeks before random-
zation. Patients were randomly assigned, double-blind, to
eceive 10-mg rosuvastatin or matching placebo once daily.
Baseline assessments including symptoms, medical his-
ory, examination, and documentation of a low LVEF,
sually by echocardiography, were recorded. Blood tests
ere done at the end of the run-in period before random-
zation. Patients were not required to rest or fast before
esting. NT-proBNP was analyzed at a central laboratory
sing a commercially available assay (Roche Diagnostics,
asel, Switzerland).
The steering committee designed the trial and supervised
ts conduct in collaboration with representatives of the
tudy’s sponsor, AstraZeneca (Mölndal, Sweden). The
ponsor collected the trial data.
nalysis plan. Variables included in the analyses are shown
y tertile of NT-proBNP in Table 1. Continuous variables
hat were not normally distributed, such as NT-proBNP,
ere expressed as median and interquartile range, and for
odeling purposes, a natural log transformation was used.
The main objective was to investigate the effects of
osuvastatin according to the plasma concentration of NT-
roBNP for various cardiovascular outcomes. The primary
utcome was the composite of cardiovascular mortality,
onfatal myocardial infarction (MI), or nonfatal stroke,
nalyzed as the time to the first event. The secondary
utcomes were (in listed order): all-cause mortality; any
oronary event (defined as sudden death, fatal or nonfatal
I, coronary revascularization, ventricular defibrillation by
n implantable defibrillator, resuscitation from cardiac ar-
est, or hospitalization for unstable angina); cardiovascular
ortality (cause-specific cardiovascular death was also ana-
yzed); and total number (episodes) of hospitalizations (for
ll causes, cardiovascular causes, unstable angina, and wors-
ning heart failure). We also included 2 additional post hoc
omposite outcomes: death from any cause or hospitaliza-
ion for worsening heart failure, which is commonly re-
orted in heart failure trials, and an atherothrombotic end
oint (fatal or nonfatal MI or fatal or nonfatal nonhemor-
hagic stroke) constituting events likely to be related to
therosclerothrombosis rather than myocardial disease. The
efinition and adjudication of all outcomes were previously
escribed in detail (14).
Cox proportional hazards models were used to calcu-
Abbreviations
and Acronyms
HR  hazard ratio
LVEF  left ventricular
ejection fraction
MI  myocardial infarction
NT-proBNP  amino-
terminal pro-brain
natriuretic peptideate the hazard ratios (HRs) and 95% confidence intervals
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ertiles of NT-proBNP (SAS version 8.2, Stata Corp.,
ollege Station, Texas), both unadjusted Cox and ad-
usted for the pre-specified risk factors that were included
aseline Characteristics by Tertiles of NT-proBNPTable 1 Baseline Characteristics by Tertiles of NT-proBNP
Variables
Tertile 1
(n  1,221)
NT-proBNP (pmol/l) 102.7
NT-proBNP (pg/ml) 868
Clinical characteristics
Age, yrs 70.8 (6.7)
75 yrs, n (%) 379 (31)
Female sex, n (%) 318 (26)
NYHA functional class III or IV, n (%) 762 (62)
Ejection fraction, % 0.33 (0.06)
BMI, kg/m2 28.4 (4.7)
Systolic blood pressure, mm Hg 132 (16)
Diastolic blood pressure, mm Hg 78 (8.5)
Heart rate, beats/min 69 (10)
Current smoker, n (%) 116 (10)
Medical history, n (%)
Myocardial infarction 717 (59)
CABG or PTCA/PCI 328 (27)
Hypertension 847 (69)
Diabetes mellitus 353 (29)
Atrial fibrillation* 87 (7.1)
Stroke 131 (11)
Pacemaker 80 (7)
Defibrillator 29 (2)
Laboratory measurements
Total cholesterol, mmol/l† 5.53 (1.07)
LDL cholesterol, mmol/l† 3.71 (0.95)
HDL cholesterol, mmol/l† 1.21 (0.33)
ApoA-I, g/l 1.52 (0.26)
ApoB, g/l 1.31 (0.30)
Triglycerides, mmol/l‡ 2.20 (1.31)
Serum creatinine, mol/l§ 107 (23)
eGFRMDRD, ml/min/1.73 m
2 61 (14)
eGFRMDRD 60 ml/min/1.73 m
2, n (%) 564 (46)
NT-proBNP, pmol/l 47 (26–78)
hsCRP, mg/l¶ 2.9 (1.4–6.1)
Medication, n (%)
Loop diuretic 757 (62)
Loop or thiazide-like diuretic 1020 (84)
Aldosterone antagonist 394 (32)
ACE inhibitor 1004 (82)
ACE inhibitor or ARB 1133 (93)
Beta-blocker 920 (75)
Digitalis glycoside 249 (20)
Antiarrhythmic therapy 139 (11)
Antiplatelet therapy 840 (69)
Anticoagulation therapy 274 (22)
alues are given as mean (SD) unless stated otherwise. Conversion factor for NT-proBNP: 1 pmol/
g/dl, divide by 88.5. §To convert to mg/dl, multiply by 0.0113. Measured in 1,820 placebo-ass
ACE angiotensin-converting enzyme; ApoA-I apolipoprotein I; ApoB apolipoprotein B; A
GFR  estimated glomerular filtration rate; HDL  high-density lipoprotein; hsCRP  high-se
A not applicable; NT-proBNP amino-terminal pro-brain natriuretic peptide; NYHA New Y
oronary angioplasty.n the optimal allocation procedure at randomization vage; sex; ejection fraction; New York Heart Associa-
ion functional class; history of MI, hypertension, and
iabetes mellitus; total cholesterol; and beta-blocker use).
or unadjusted Cox proportional hazards models, the p
Tertile 2
(n  1,222)
Tertile 3
(n  1,221) p Value
102.7–277.5 277.5 NA
868–2,347 2,347 NA
72.7 (7.0) 74.5 (7.2) 0.00001
488 (40) 624 (51) 0.00001
288 (24) 289 (24) 0.1720
769 (62) 822 (67) 0.0115
0.31 (0.06) 0.29 (0.07) 0.00001
27.3 (4.5) 25.9 (4.2) 0.00001
130 (16) 126 (17) 0.00001
77 (8.5) 74 (9.3) 0.00001
72 (11) 73 (12) 0.00001
106 (9) 87 (7) 0.0568
701 (57) 703 (58) 0.5662
302 (25) 300 (25) 0.1930
783 (64) 734 (60) 0.00001
360 (30) 365 (30) 0.5942
338 (28) 449 (37) 0.00001
156 (13) 177 (15) 0.0051
145 (12) 185 (15) 0.00001
45 (4) 35 (3) 0.4749
5.41 (1.04) 5.06 (1.13) 0.00001
3.59 (0.90) 3.36 (0.96) 0.00001
1.26 (0.36) 1.23 (0.36) 0.3503
1.53 (0.28) 1.45 (0.29) 0.00001
1.27 (0.29) 1.19 (0.30) 0.00001
2.02 (1.42) 1.67 (1.02) 0.00001
113 (27) 123 (30) 0.00001
59 (14) 53 (14) 0.00001
661 (54) 832 (68) 0.00001
173 (133–220) 485 (364–776) NA
3.1 (1.4–6.8) 4.6 (1.9–12.2) 0.00001
933 (76) 1089 (89) 0.00001
1070 (88) 1152 (94) 0.00001
494 (40) 576 (47) 0.00001
1007 (82) 963 (79) 0.0339
1136 (93) 1106 (91) 0.0427
943 (77) 936 (77) 0.4459
424 (35) 498 (41) 0.00001
161 (13) 132 (11) 0.6605
722 (59) 626 (51) 0.00001
462 (38) 542 (44) 0.00001
57 pg/ml. *Current on electrocardiogram. †To convert to mg/dl, multiply by 38.6. ‡To convert to
nd 1,844 rosuvastatin-assigned patients. ¶Median (interquartile range).
ngiotensin receptor blocker; BMI body mass index; CABG coronary artery bypass grafting;
y C-reactive protein; LDL  low-density lipoprotein; MDRD  Modified Diet in Renal Disease;
rt Association; PCI percutaneous coronary intervention; PTCA percutaneous transluminall  8.4
igned a
RB a
nsitivitalues are determined by the log-rank test. The total
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November 10, 2009:1850–9 CORONA: NT-proBNP and Rosuvastatinumbers of hospitalizations were analyzed with a permu-
ation test.
The associations between [loge]NT-proBNP and the
reviously cited outcomes were investigated in multivariable
odels (17). Each analysis was conducted with and without
he exclusion of NT-proBNP and high-sensitivity C-reactive
rotein to identify factors that they displaced or drew in when
ntered into the model. The relationship between [loge]NT-
roBNP and the number of events per 100 patient-years of
ollow-up was also expressed using a cubic-spline function with
Rs adjusted for age, history of diabetes, coronary bypass or
laudication, New York Heart Association functional class,
eart rate and rhythm, systolic blood pressure, and ejection
raction. The 95% CIs were estimated using the bootstrap
ethod with 1,000 resubstitutions.
esults
f 5,011 patients enrolled in CORONA, a measurement of
T-proBNP was available for 3,664 (73%) and showed a
ighly skewed distribution (Fig. 1). The characteristics of
atients with and without a measurement of NT-proBNP
ere similar (data not shown). Patients in the highest tertile
f NT-proBNP (277 pmol/l [2,348 pg/ml]) had, on
verage, many other markers of a worse prognosis (Table 1).
atients with plasma concentrations in the lowest tertile of
T-proBNP (103 pmol/l [868 pg/ml]) were younger;
ere more likely to have mild symptoms, a higher body
ass index, systolic blood pressure, and cholesterol; were
ess likely to have rhythm disturbances, renal dysfunction, or
ncreased high-sensitivity C-reactive protein; and were less
ikely to receive loop diuretics, aldosterone antagonists, or
igoxin (Table 1). Sex, LVEF, and the proportions treated
ith angiotensin-converting enzyme inhibitors and beta-
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Figure 1 Distribution of Plasma
Concentrations of NT-proBNP at Baseline
Arrows mark the tertile boundaries. Conversion factor for amino-terminal
pro-brain natriuretic peptide (NT-proBNP): 1 pmol/l  8.457 pg/ml.lockers were similar across tertiles. Within each tertile, the tharacteristics in the 2 randomization groups were very
imilar (data not shown).
T-proBNP and rates of events. The risk of events
ncreased exponentially when plotted against [loge]NT-
roBNP as a continuous function (Fig. 2). The risk of death
rom heart failure was low in patients with NT-proBNP
50 pmol/l (423 pg/ml). The risk of sudden death began to
ncrease at somewhat lower levels. There was a marked and
rogressive increase in the rate of each outcome of interest,
part from nonfatal vascular events, with each increasing
ertile of NT-proBNP (numbers given in Fig. 3).
Multivariable analyses demonstrated that NT-proBNP
as more strongly associated with each specified outcome
han any other measured variable. The relationship between
T-proBNP was strongest for death or hospitalization for
orsening heart failure, weaker for sudden death, and
eakest for atherothrombotic events (Table 2). Few vari-
bles added substantially to the model fit for most outcomes.
liminating NT-proBNP from the models generally in-
reased the strength of association between outcome and
VEF, serum creatinine, body mass index, higher heart
ate, and apolipoprotein A-I. Conversely, when NT-
roBNP was included in the models, atrial fibrillation was
ore strongly associated with an adverse outcome and
emale sex with a more favorable outcome.
hange in lipids and lipoproteins during follow-up. For
ach tertile of NT-proBNP, rosuvastatin exerted a similar
et percentage mean decrease versus placebo in low-density
ipoprotein from baseline to the 3-month follow-up visit
47% [95% CI: 45% to 49%], 45% [95% CI: 43% to 48%],
nd 43% [95% CI: 41% to 46%]; p  0.0001 for all) in low,
iddle, and upper tertiles, respectively; triglycerides (20%
95% CI: 15% to 24%], 22% [95% CI: 18% to 26%], and
0% [95% CI: 16% to 25%]; p  0.0001 for all), and a
imilar percentage increase in high-density lipoprotein (7%
95% CI: 4% to 8%], 5% [95% CI: 3% to 7%], and 5% [95%
I: 3% to 7%]; p  0.0001 for all). For each tertile of
T-proBNP, rosuvastatin exerted a similar net percentage
edian decrease in high-sensitivity C-reactive protein from
aseline to the closing visit (37%, 37%, and 35%; p 
.0001, p  0.0001, and p  0.0002, respectively).
nteraction between the effects of rosuvastatin and NT-
roBNP. The Cox adjusted HR (0.65, 95% CI: 0.47 to
.88; p  0.005) for the primary end point among patients
n the lowest tertile of NT-proBNP favored those assigned
o rosuvastatin, and tests suggested heterogeneity for the
ffect of rosuvastatin (p 0.0192) on the primary end point
cross NT-proBNP tertiles (Fig. 3). This effect was driven
y a combination of fewer MIs, strokes, and cardiovascular
eaths in the lowest tertile. Trends were similar for most
ther outcomes, except death from heart failure, for which
here were very few events in the first tertile (Fig. 3). There
as also a reduction in hospitalizations for cardiovascular
easons and for worsening heart failure in patients within
he lowest tertile of NT-proBNP assigned to rosuvastatin
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CORONA: NT-proBNP and Rosuvastatin November 10, 2009:1850–9Table 3), with less certain evidence of benefit among
atients in the upper 2 tertiles.
olerability. Discontinuation from randomized treatment
ncreased with increasing NT-proBNP values in both the
lacebo and rosuvastatin groups, however, with fewer dis-
ontinuations of rosuvastatin compared with placebo in all 3
ertiles, significantly so in the lowest tertile (131 patients
eceiving placebo and 91 receiving rosuvastatin, 9.0 vs. 6.2
er 100 patient-years of follow-up, HR: 0.69, 95% CI: 0.53
o 0.91; p  0.0068) compared with the middle tertile (122
atients vs. 113 patients, 8.9 vs. 8.2 per 100 patient-years of
ollow-up, HR: 0.92; p  NS) and upper tertile (157
atients vs. 153 patients, 14.5 vs. 12.7 per 100 patient-
ears of follow-up, HR: 0.88; p  NS).
iscussion
his post hoc analysis of CORONA confirms, in patients
ith heart failure and ischemic heart disease, that elevated
lasma concentrations of NT-proBNP are associated with
any other variables that predict an adverse prognosis; that
T-proBNP is a powerful predictor of many cardiovascular
utcomes including atherothrombotic vascular events, sud-
Figure 2 Relationship Between [loge]NT-proBNP and the Annua
Relationship between [loge]NT-proBNP (x-axis) and the annual rate of the primary o
posite of all-cause mortality or hospitalization for heart failure (y-axis). Rates of de
model that calculated the risk for a 70-year-old man with a left ventricular ejection
and with a baseline heart rate of 70 beats/min and systolic blood pressure of 13
in Figure 1.en death, and especially heart failure; and that few other rlinical or laboratory variables add substantially to its ability
o predict outcome. Patients with lower plasma concentra-
ions of NT-proBNP had a lower event rate but seemed to
btain greater benefit from rosuvastatin. This occurred
espite similar effects of rosuvastatin on lipid profile and
igh-sensitivity C-reactive protein in each tertile of NT-
roBNP. Fewer patients withdrew from rosuvastatin than
lacebo in the lowest tertile. The rates of discontinuation of
osuvastatin and placebo in patients in the upper 2 tertiles of
T-proBNP were similar and seemed unlikely to account
or the lack of benefit.
There is extensive literature on the potential diagnostic
nd prognostic utility of natriuretic peptides, although few
tudies are as large as CORONA (8). Plasma concentrations
f NT-proBNP 50 pmol/l (approximately 423 pg/ml),
uggesting mild and/or well-controlled heart failure (18),
ere recorded in 25% of patients. Most patients in
ORONA had grossly elevated levels of NT-proBNP, similar
o those observed in studies of moderate or severe heart failure
uch as the CARE-HF (Cardiac Resynchronization-Heart
ailure) trial (19,20), although the relationship to New York
eart Association functional class was not strong, perhaps
diovascular Events Rates
e measure, sudden death, death from worsening heart failure, and for the com-
r events are expressed as per 100 patient-years. The example is derived from a
n of 30%, of New York Heart Association functional class III, without diabetes,
Hg. Conversion factor for NT-proBNP: 1 pmol/l  8.457 pg/ml. Abbreviation asl Car
utcom
aths o
fractio
0 mmeflecting the variability of symptom classification provided by
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November 10, 2009:1850–9 CORONA: NT-proBNP and Rosuvastatinlinicians and protocol-driven patient selection (21). Previous
eports suggest that plasma concentrations of natriuretic pep-
Favors
Rosuvastatin
Favo
Place
Primary Endpoint
Tertile 1
Tertile 2
Tertile 3
All randomized
No. of events (rate)
Placebo/ Rosuvastatin
105(6.8)/67(4.4)
138(9.5)/152(10.5)
243(20.7)/262(20.3)
732(12.3)/692(11.4)
Relative risk (95% 
1.00.5
102(6.6)/74(4.9)
125(8.8)/126(8.9)
176(15.3/186(14.7)
588(10.0)/554(9.3)
Coronary Endpoint
Tertile 1
Tertile 2
Tertile 3
All randomized
Atherothrombotic Endpoint
Tertile 1
Tertile 2
Tertile 3
All randomized
All-cause mort./hosp. HF
Tertile 1
Tertile 2
Tertile 3
All randomized
160(10.7)/119(8.0)
243(18.3)/251(19.2)
382(39.9)/380(35.3)
1112(20.5)/1056(19.1)
55(3.5)/33(2.2)
49(3.4)/49(3.4)
53(4.5)/65(5.0)
255(4.3)/212(3.5)
Favors
Rosuvastatin
Favors
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Figure 3 Interactions Between Tertiles of NT-proBNP and Rosu
(A) Primary end point, coronary end point, atherothrombotic end point, and compo
event) in the 3 tertiles of NT-proBNP showing hazard ratios (HRs) with 95% confide
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CORONA: NT-proBNP and Rosuvastatin November 10, 2009:1850–9ultivariable Analyses Performed With and Without NT-proBNP and hsCRP Included in theORONA Multivariable Model (17) for a Range of Pre-Specified E Points a d for 2 Post-Hoc End PointsTable 2 Multivariable Analyses Performed With and Without NT-proBNP and hsCRP Included in theCORONA Multivariable Model (17) for a Range of Pre-Specified End Points and for 2 Post-Hoc End Points
Variable
NT-proBNP and hsCRP Included NT-proBNP and hsCRP Excluded
Hazard Ratio Wald Chi-Square Test p Value Hazard Ratio Wald Chi-Square Test p Value
Primary end point: 883 events
Log NT-proBNP 1.587 155.445 <0.0001 — — —
Age/10 1.257 18.727 <0.0001 1.289 23.485 <0.0001
Atrial fibrillation* 1.406 16.911 <0.0001 1.086 1.003 0.3167
Diabetes mellitus 1.347 15.776 <0.0001 1.413 21.288 <0.0001
Claudication 1.356 10.662 0.0011 1.381 12.030 0.0005
CABG 0.741 9.005 0.0027 0.752 8.179 0.0042
NYHA functional class III or IV 1.255 8.698 0.0032 1.308 12.160 0.0005
Apo A-I* 0.689 7.771 0.0053 0.527 22.394 <0.0001
Ejection fraction* 0.985 7.629 0.0057 0.971 30.661 <0.0001
Women* 0.782 7.491 0.0062 0.887 1.759 0.1847
Previous MI 1.206 6.568 0.0104 1.204 6.480 0.0109
SBP/10 0.957 3.968 0.0464 0.946 6.217 0.0127
Creatinine/10* 1.009 0.457 0.4988 1.058 22.086 <0.0001
BMI* 0.984 3.142 0.0763 0.961 20.754 <0.0001
Heart rate/10 1.060 3.606 0.0576 1.118 13.245 0.0003
Triglycerides 0.985 0.210 0.6466 0.907 7.935 0.0048
Overall model fit 477.1 0.0001 314.9 0.0001
Mortality: 934 events
Log NT-proBNP 1.597 166.719 <0.0001 — — —
Age/10 1.259 20.154 <0.0001 1.295 25.935 <0.0001
Diabetes mellitus 1.309 13.345 0.0003 1.362 17.699 <0.0001
Ejection fraction* 0.982 11.510 0.0007 0.968 41.315 <0.0001
BMI* 0.970 11.313 0.0008 0.946 39.702 <0.0001
CABG 0.725 10.858 0.0010 0.743 9.407 0.0022
Women* 0.745 10.757 0.0010 0.847 3.375 0.0662
Atrial fibrillation* 1.297 10.695 0.0011 1.012 0.023 0.8804
NYHA functional class III or IV 1.275 10.457 0.0012 1.331 14.491 0.0001
Apo A-I* 0.667 9.595 0.0020 0.515 25.267 <0.0001
Creatinine/10* 1.036 8.504 0.0035 1.081 47.767 <0.0001
Claudication 1.274 7.136 0.0076 1.327 9.858 0.0017
Heart rate/10* 1.069 5.115 0.0237 1.125 16.132 <0.0001
Previous MI 1.150 3.879 0.0489 1.148 3.766 0.0523
Triglycerides* 0.973 0.701 0.4024 0.896 9.910 0.0016
SBP/10 0.968 2.306 0.1289 0.956 4.527 0.0334
Overall model fit 600.4 <0.0001 440.2 <0.0001
Coronary events: 741 events
Log NT-proBNP 1.469 95.579 <0.0001 — — —
Atrial fibrillation* 1.533 20.692 <0.0001 1.213 4.324 0.0376
Diabetes mellitus 1.305 10.633 0.0011 1.366 14.665 0.0001
Apo A-1* 0.652 8.445 0.0037 0.527 18.456 <0.0001
Claudication 1.330 7.615 0.0058 1.344 8.201 0.0042
Angina pectoris 1.283 7.568 0.0059 1.231 5.293 0.0214
Previous MI 1.226 6.443 0.0111 1.230 6.610 0.0101
Ejection fraction* 0.987 4.594 0.0321 0.975 19.479 <0.0001
NYHA functional class III or IV 1.193 4.452 0.0349 1.241 6.663 0.0098
SBP/10 0.953 4.001 0.0455 0.945 5.328 0.0210
BMI* 0.990 1.154 0.2827 0.970 10.693 0.0011
Creatinine/10* 0.993 0.227 0.6335 1.039 7.776 0.0053
Heart rate/10* 1.048 1.868 0.1718 1.099 7.715 0.0055
Age/10 1.107 3.130 0.0769 1.135 4.896 0.0269
Overall model fit 291.0 <0.0001 182.3 <0.0001
Atherothrombotic end point: 284 events
Log NT-proBNP 1.238 11.719 0.0006 — — —
Previous MI 1.477 8.597 0.0034 1.494 9.126 0.0025
Atrial fibrillation 1.569 7.886 0.0050 1.356 3.782 0.0518Continued on next page
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Variable
NT-proBNP and hsCRP Included NT-proBNP and hsCRP Excluded
Hazard Ratio Wald Chi-Square Test p Value Hazard Ratio Wald Chi-Square Test p Value
Log hsCRP 1.007 7.408 0.0065 — — —
Age/10 1.284 7.057 0.0079 1.304 8.025 0.0046
Claudication 1.392 4.211 0.0402 1.409 4.547 0.0330
Diabetes mellitus 1.296 3.856 0.0496 1.324 4.535 0.0332
Apo A-I 0.654 3.153 0.0758 0.535 6.698 0.0097
Overall model fit 97.7 <0.0001 73.8 <0.0001
Sudden death: 407 events
Log NT-proBNP 1.688 90.097 <0.0001 — — —
Ejection fraction* 0.977 8.555 0.0034 0.962 26.403 <0.0001
Age/10 1.207 5.828 0.0158 1.244 8.080 0.0045
Apo A-I* 0.623 5.650 0.0175 0.492 12.396 0.0004
CABG 0.700 5.645 0.0175 0.727 4.579 0.0324
Diabetes mellitus 1.298 5.530 0.0187 1.369 8.062 0.0045
Atrial fibrillation* 1.322 5.412 0.0200 0.997 0.001 0.9769
Women 0.738 4.966 0.0258 0.852 1.369 0.2421
NYHA functional class III or IV 1.197 2.570 0.1089 1.260 4.264 0.0389
Creatinine/10* 1.027 2.082 0.1491 1.078 19.393 <0.0001
BMI* 0.989 0.686 0.4074 0.962 8.953 0.0028
Overall model fit 246.0 <0.0001 163.4 <0.0001
WHF deaths: 230 events
Log NT-proBNP 1.986 82.637 <0.0001 — — —
Age/10 1.396 10.478 0.0012 1.438 12.793 0.0003
Diabetes mellitus 1.574 9.696 0.0018 1.656 12.158 0.0005
CABG 0.511 8.284 0.0040 0.522 7.918 0.0049
NYHA functional class III or IV 1.549 7.748 0.0054 1.610 9.204 0.0024
Heart rate/10* 1.163 6.999 0.0082 1.251 16.028 <0.0001
Atrial fibrillation* 1.498 6.790 0.0092 1.120 0.539 0.4630
SBP/10 0.896 6.451 0.0111 0.871 10.020 0.0015
Ejection fraction* 0.976 5.627 0.0177 0.957 20.810 <0.0001
Claudication 1.456 4.433 0.0352 1.504 5.323 0.0210
Creatinine/10* 1.038 2.499 0.1139 1.100 18.578 <0.0001
BMI* 0.968 3.210 0.0732 0.933 14.688 0.0001
Apo A-I* 0.832 0.515 0.4731 0.547 5.449 0.0196
Smoking 0.632 2.529 0.1118 0.563 3.998 0.0456
Overall model fit 295.8 <0.0001 223.0 <0.0001
Death or WHF: 1,376 events
Log NT-proBNP 1.639 259.612 <0.0001 — — —
NYHA functional class III or IV 1.381 26.597 <0.0001 1.444 34.577 <0.0001
Heart rate per 10 beats/min 1.122 21.993 <0.0001 1.172 42.318 <0.0001
Diabetes mellitus 1.294 18.366 <0.0001 1.352 25.260 <0.0001
Ejection fraction* 0.985 12.624 0.0004 0.970 54.320 <0.0001
Apo A-I* 0.686 12.181 0.0005 0.547 30.320 <0.0001
Age/10 1.140 9.501 0.0021 1.178 15.111 0.0001
Women* 0.828 7.045 0.0079 0.943 0.666 0.4145
Claudication 1.216 6.532 0.0106 1.271 9.940 0.0016
Atrial fibrillation 1.151 4.763 0.0291 0.863 5.383 0.0203
Creatinine/10* 1.015 2.168 0.1409 1.064 40.602 <0.0001
BMI* 0.997 0.194 0.6593 0.973 15.896 <0.0001
Triglycerides* 0.988 0.235 0.6281 0.913 11.404 0.0007
SBP/10 0.967 3.653 0.0560 0.956 6.486 0.0109
Overall model fit 700.8 <0.0001 463.0 <0.0001
dapted from Wedel et al. (17). Values in bold indicate strong associations (p  0.0001). The 2 atherothrombotic end points: composite of fatal and nonfatal myocardial infarction and fatal or nonfatal
onhemorrhagic stroke and also the composite of all-cause mortality or hospitalization for worsening heart failure (n  3,342). *A major change in the strength of the association with the outcome with
he inclusion of NT-proBNP and high-sensitivity C-reactive protein in the model.
Apo A-I  apolipoprotein A-I; BMI  body mass index; CABG  coronary artery bypass graft; CORONA  Controlled Rosuvastatin Multinational Trial in Heart Failure; hsCRP  high-sensitivity
-reactive protein; MI  myocardial infarction; NT-proBNP  amino-terminal brain natriuretic peptide; NYHA  New York Heart Association; SBP  systolic blood pressure; WHF  worsening heart
ailure; /10  per change in 10 U.
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CORONA: NT-proBNP and Rosuvastatin November 10, 2009:1850–9t is perhaps because NT-proBNP reflects so many prognostic
ariables that it is itself such a powerful predictor of prognosis.
onversely, the multivariable models suggest that the associa-
ion between NT-proBNP and outcome is only partially
xplained by the previously cited factors because the model has
ess predictive power when NT-proBNP is dropped. Of
articular interest was the strengthening of the relationship
etween a favorable outcome and female sex when NT-
roBNP was included in the model. Healthy women are
nown to have higher plasma concentrations of NT-proBNP
22), and women may have a better prognosis than men for a
iven value of NT-proBNP. Patients with atrial fibrillation
lso have higher plasma concentrations of NT-proBNP,
hether or not they have clinical heart failure, and they too
eem to have a better prognosis than suggested by their plasma
T-proBNP level (23). LVEF differed little across tertiles of
T-proBNP. This could reflect the inaccuracy of echocardio-
raphic measurements, but the numbers in each group are large
nd the lack of accuracy should increase variability but not
ffect mean values for LVEF. Plasma concentrations of NT-
roBNP may also reflect diastolic left ventricular function (6),
trial fibrillation, valve dysfunction, and, most importantly in
he context of CORONA, mitral regurgitation. Accordingly, a
trong relationship between LVEF and NT-proBNP should
ot be expected. This has important implications for the
iagnostic use of natriuretic peptides, which may not perform
ell when used solely to predict the presence of left ventricular
ystolic dysfunction rather than the more general problem of
ardiac dysfunction.
Because natriuretic peptides reflect many aspects of car-
iac function, it is not surprising that the strongest relation-
hip is with hospitalization or death due to worsening heart
ailure. Because such events account for a high proportion of
ardiovascular events, it is also not surprising that natriuretic
eptides predict cardiovascular hospitalization and death.
owever, NT-proBNP was also a powerful predictor of
otal Number (Episodes) ofspitalizations According to Tertile of NT-proBNPTable 3 Total Number (Episodes) ofHospitalizations According to Tertile of NT-proBNP
Hospitalizations
Placebo
n (rate)*
Rosuvastatin
n (rate)* p Value†
All-cause
Tertile 1 785 (48.5) 594 (38.0) 0.0182
Tertile 2 930 (62.0) 896 (60.1) 0.56
Tertile 3 1,182 (97.0) 1,130 (84.9) 0.080
Cardiovascular
Tertile 1 467 (28.9) 303 (19.4) 0.0008
Tertile 2 558 (37.2) 528 (35.4) 0.51
Tertile 3 801 (65.7) 738 (55.4) 0.054
Worsening HF
Tertile 1 191 (11.8) 85 (5.4) 0.0002
Tertile 1 237 (15.9) 249 (16.7) 0.79
Tertile 3 506 (41.5) 447 (33.6) 0.048
tatistically significant comparisons are indicated in bold. *Events per 100 patient-years of
ollow-up. †Statistical analysis using a permutation test.
HF  heart failure; NT-proBNP  amino-terminal brain natriuretic peptide.udden death. Assuming that such events predominantly Deflect ventricular arrhythmias and knowing that the severity
f left ventricular dysfunction is a powerful predictor of
rrhythmias, this is also not surprising. Other predisposing
actors such as myocardial electrical re-entry pathways that
re not entirely dependent on the severity of ventricular
amage, may weaken its relationship to NT-proBNP.
owever, some sudden deaths may be vascular in origin.
T-proBNP was a relatively poor predictor of athero-
hrombotic events compared with other measured out-
omes. Few patients with advanced heart failure are likely to
urvive a further substantial vascular event, which may
nstead be recorded as sudden death, either because it
ccurred rapidly or because patients were found dead,
aving been unable to call for help after the onset of
ymptoms.
The Heart Protection Study suggested that the rela-
ive, but not the absolute, benefits of simvastatin declined
s NT-proBNP increased (10). The CORONA data are
onsistent with this observation and extend the observa-
ion to patients with much higher plasma concentrations
f NT-proBNP (16). Low plasma concentrations should
rigger a review of the clinical evidence for the diagnosis
f heart failure and its associated treatment. Perhaps
atients who have heart failure, left ventricular systolic
ysfunction, and ischemic heart disease with NT-
roBNP of a magnitude similar to that found in the first
ertile of NT-proBNP in CORONA should receive a
tatin, but treatment may be futile in patients with heart
ailure and markedly elevated plasma concentrations (24).
owever, the analysis also suggests that statins are not
armful in patients with advanced heart failure and might
e used in such patients when the patient and physician
onsider it appropriate.
This is a retrospective analysis, and, ideally, the results
hould be confirmed in a prospective study. It is unlikely
hat patients or physicians would be willing to participate
n further placebo-controlled trials of statins in patients
ith ischemic heart disease and NT-proBNP 103
mol/l, but trials of statins or other agents that alter the
ipid profile in patients with higher levels might be
onsidered. The biological variability in plasma concen-
rations of NT-proBNP is large, and the relationship
etween NT-proBNP and therapeutic benefit from rosu-
astatin is probably modified by other patient character-
stics. Accordingly, plasma values of NT-proBNP should
e used for general guidance rather than for precise rule
etting. Plasma concentrations of NT-proBNP cannot be
quated precisely with those of brain natriuretic peptide,
or which a variety of different assays exists. However, an
T-proBNP plasma concentration of 100 pmol/l (846
g/ml) equates to a brain natriuretic peptide value of
pproximately 200 pg/ml using the Biosite assay (Biosite,
an Diego, California) or ADVIA Centaur assay (Bayer
iagnostics, Tarrytown, New York) (25).
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he CORONA and the Heart Protection Study findings
re consistent and suggest that the relative benefits of statins
ecline as the plasma concentration of NT-proBNP in-
reases so that an effect is no longer apparent above values of
pproximately 103 pmol/l (868 pg/ml). These data support
he use of statin therapy in patients with coronary disease
nd less advanced heart failure.
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